3-(4'-Pyridyl)-D-alanine
Need Assistance?
  • US & Canada:
    +
  • UK: +

3-(4'-Pyridyl)-D-alanine

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

3-(4'-Pyridyl)-D-alanine is a derivative of alanine which is an amino acid that is commonly found in bacteria, such as Streptococcus faecalis. Alanine is essential for the biosynthesis of peptidoglycan crosslinking sub-units that are used for bacterial cell walls. D-Alanine is also known to cause cytotoxic oxidative stress in brain tumour cells.

Category
D-Amino Acids
Catalog number
BAT-007808
CAS number
37535-50-5
Molecular Formula
C8H10N2O2
Molecular Weight
166.18
3-(4'-Pyridyl)-D-alanine
IUPAC Name
(2R)-2-amino-3-pyridin-4-ylpropanoic acid
Synonyms
D-Ala(4'-pyridyl)-OH; (R)-2-Amino-3-(4'-pyridyl)propanoic acid; D-4-PYRIDYLALANINE; 3-(4-Pyridyl)-D-alanine; (R)-2-Amino-3-(pyridin-4-yl)propanoic acid; (2R)-2-amino-3-(pyridin-4-yl)propanoic acid; BETA-(4-PYRIDYL)-D-ALANINE; D-4-Pal; (2R)-2-amino-3-(4-pyridyl)propanoic acid; 4'-PYRIDYL-D-ALA; H-D-ALA(4-PYRI)-OH
Appearance
White powder
Purity
≥ 98%
Density
1.271±0.06 g/cm3 (Predicted)
Melting Point
280 °C (dec.)
Boiling Point
346.4±32.0 °C (Predicted)
Storage
Store at 2-8 °C
InChI
InChI=1S/C8H10N2O2/c9-7(8(11)12)5-6-1-3-10-4-2-6/h1-4,7H,5,9H2,(H,11,12)/t7-/m1/s1
InChI Key
FQFVANSXYKWQOT-SSDOTTSWSA-N
Canonical SMILES
C1=CN=CC=C1CC(C(=O)O)N

3-(4'-Pyridyl)-D-alanine (abbreviated as D-PalA), a non-proteinogenic amino acid featuring a pyridine ring linked to an alanine moiety, stands as a significant compound with diverse applications across several scientific and industrial domains. The molecule’s unique structural attributes—combining the reactivity of the pyridine ring with the chirality and bioactivity of the D-alanine residue—facilitate its diverse utility. Here, we will explore four key application areas of D-PalA, encompassing pharmaceuticals, biochemical research, organic synthesis, and material science.

1. Pharmaceuticals and Medicinal Chemistry One of the foremost applications of D-PalA is within the pharmaceutical industry and medicinal chemistry. The compound's intrinsic biological activity and potential to interact with various biological pathways render it useful in drug development and discovery.

a. Antimicrobial Activity: Pyridine derivatives are known for their antimicrobial properties. The incorporation of such derivatives into amino acids like D-PalA can enhance the antimicrobial spectrum, aiding in the design of novel antibacterial and antifungal drugs. These compounds can disrupt bacterial cell walls or inhibit protein synthesis, providing an expansive mechanism of action.

b. Enzyme Inhibition: D-PalA can function as a pseudo-substrate or an inhibitor of enzymes involving D-alanine. This can be particularly valuable in the development of drugs targeting specific bacterial or fungal enzymes that are not present in human cells, potentially minimizing off-target effects.

c. Drug Transport and Targeting: The pyridine moiety may facilitate binding to specific receptors or transporters, aiding in the targeted delivery of therapeutic agents. This targeting can improve the efficacy and reduce the side effects of drugs, enhancing patient outcomes.

2. Biochemical and Physiological Research D-PalA’s unique structure makes it an excellent tool for biochemical and physiological studies. Researchers exploit its properties to elucidate biological mechanisms and protein functions.

a. Protein and Peptide Engineering: The incorporation of D-PalA into peptides can help study protein folding, structure, and dynamics. The D-alanine residue increases resistance to enzymatic degradation, enabling more stable and longer-lasting peptide drugs or probes in vivo.

b. Enzyme Study and Mechanism Elucidation: D-amino acids are integral in studying enzymatic mechanisms, particularly those of D-amino acid oxidases, peptidases, and racemases. By employing D-PalA, researchers can investigate the stereochemical preferences and catalytic activities of these enzymes, contributing to a deeper understanding of their physiological roles.

c. Cellular and Molecular Probes: Fluorescent or radiolabelled derivatives of D-PalA can serve as molecular probes, facilitating the imaging and tracking of biological processes at the cellular and subcellular levels. Such probes are indispensable in modern cell biology and biochemistry.

3. Organic Synthesis and Chemical Transformations In synthetic chemistry, D-PalA offers significant utility due to its bifunctional nature—combining the amino acid side-chain chemistry with the reactivity of the pyridine ring for diverse synthetic applications.

a. Building Blocks for Complex Molecules: The chiral center and functional groups of D-PalA make it a valuable building block for synthesizing more complex organic molecules and pharmacophores. It serves as an intermediate in constructing heterocyclic frameworks and chiral centers necessary for asymmetric synthesis.

b. Catalyst and Ligand Design: The pyridine ring of D-PalA facilitates coordination with metal ions, making it a potential ligand for catalysis. In asymmetric catalysis, specifically, D-PalA-derived ligands can enhance enantioselectivity and catalytic efficiency, broadening the scope of feasible organic transformations.

c. Polymer and Material Synthesis: The reactivity of the amino and carboxyl groups enables polymerization or conjugation reactions, where D-PalA can be used to synthesize novel polymeric materials with specific properties, such as chirality, solubility, or binding affinity.

4. Material Science and Nanotechnology D-PalA's structural attributes also extend its applicability into material science and nanotechnology, where it contributes to developing advanced materials and nanodevices.

a. Surface Modification and Coatings: D-PalA can be employed to modify surfaces, enhancing their interaction with biological molecules. This is especially relevant in the development of biosensors, where surface modifications can improve sensitivity and specificity.

b. Nanomaterials and Drug Delivery Systems: Incorporating D-PalA into nanomaterials, like nanoparticles or nanofibers, can facilitate the controlled release of drugs. The functional groups of D-PalA improve the binding and stabilization of active pharmaceutical ingredients, optimizing their therapeutic performance.

c. Smart Materials: The responsive nature of materials incorporating D-PalA can be harnessed to create smart materials that change behavior in response to environmental stimuli (pH, temperature, or the presence of specific molecules). This is useful in creating responsive drug delivery systems or adaptive coatings.

1. Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer
Weijing Sun, James P Stevenson, James M Gallo, Maryann Redlinger, Daniel Haller, Kenneth Algazy, Bruce Giantonio, Hector Alila, Peter J O'Dwyer Clin Cancer Res. 2002 Oct;8(10):3100-4.
CP-461 is a member of a class of novel proapoptotic drugs that specifically inhibit cyclic GMP phosphodiesterases but not cyclooxygenase-1 or -2. CP-461 inhibits the growth of a broad range of human tumor cell lines in vitro at micromolar concentrations and selectively induces apoptosis in cancer cell lines but not normal cells. Preclinical studies revealed good oral bioavailability and no toxicity in dogs and rats at single doses up to 500 mg/kg. In a Phase I trial, 21 patients with a range of solid tumors and good performance status received CP-461 p.o. twice daily for 28 consecutive days. Cycles were repeated without a treatment-free interval. CP-461 doses ranged from 100 to 800 mg/day. Therapy was well tolerated overall, and a maximum tolerated dose was not reached. Grade 3 asymptomatic aspartate aminotransferase/alanine aminotransferase elevation in 1 patient treated at 800 mg/day was the only dose-limiting toxicity. No hematologic toxicity was noted. Peak plasma concentrations occurred between 1 and 2 h after dosing, and doses above 200 mg/day exceeded the known in vitro EC(50) (1-2 micro M) for apoptosis in cancer cells. No drug was detectable after 24 h of administration, and the terminal half-life was 6.7 h. The area under the plasma concentration-time curve was dose-proportional from 200 to 800 mg/day. Four patients exhibited disease stability after two cycles of treatment. CP-461 is minimally toxic at doses up to 800 mg/day when administered p.o. on a twice-daily schedule.
2. The complete amino acid sequence of the Zn2+-containing D-alanyl-D-alanine-cleaving carboxypeptidase of streptomyces albus G
B Joris, J Van Beeumen, F Casagrande, C Gerday, J M Frère, J M Ghuysen Eur J Biochem. 1983 Jan 17;130(1):53-69. doi: 10.1111/j.1432-1033.1983.tb07116.x.
The 22076-Mr Zn2+-containing D-alanyl-D-alanine-cleaving carboxypeptidase of Streptomyces abuls G effectively catalyses the transfer of the N alpha, N epsilon-diacetyl-L-lysyl-D-alanyl electrophilic group of the standard tripeptide substrate N alpha, N epsilon-diacetyl-L-lysyl-D-alanyl-D-alanine to water. It also performs a weak beta-lactamase activity, hydrolysing penicillin into penicilloate at a very low rate. This protein consists of 212 amino acid residues in a single polypeptide chain. The N terminus is partially blocked as a result of the cyclization of the dipeptide Asn-Gly into anhydroaspartylglycine imide. The protein has been fragmented by cyanogen bromide into five fragments whose sequences have been determined via appropriate subcleavages with various proteases. The ordering of the cyanogen bromide peptide fragments has been carried out (a) by submitting the S-carboxymethylated protein to complete tryptic digestion and labelling the methionine-containing peptides thus obtained with iodo[14C]-acetamide, and (b) by submitting to limited tryptic digestion the S-[2-(4'-pyridyl)ethyl]-cysteine protein whose amino groups have been blocked by reaction with exo-cis-3,6-endoxo-delta 4-tetrahydrophthalic anhydride prior to digestion. The protein contains six cysteine residues in the form of three disulfide bridges. No homology is found by comparing this peptidase with other Zn2+-containing enzymes (carboxypeptidase A, thermolysin, carbonic anhydrase B and alcohol dehydrogenase) and several completely or partially sequenced, serine-containing D-alanyl-D-alanine-cleaving peptidases and Zn2+/serine-containing beta-lactamases.
Online Inquiry
Inquiry Basket